BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29910061)

  • 1. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.
    López JI; Pulido R; Cortés JM; Angulo JC; Lawrie CH
    Pathol Res Pract; 2018 Aug; 214(8):1110-1114. PubMed ID: 29910061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
    Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
    Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma.
    López JI; Pulido R; Lawrie CH; Angulo JC
    Ann Diagn Pathol; 2018 Jun; 34():89-93. PubMed ID: 29661736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
    Lee KS; Yun S; Lee K; Moon S; Choe G
    Hum Pathol; 2020 May; 99():88-97. PubMed ID: 32246989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
    Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P
    Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
    Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
    Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.
    Iacovelli R; Nolè F; Verri E; Renne G; Paglino C; Santoni M; Cossu Rocca M; Giglione P; Aurilio G; Cullurà D; Cascinu S; Porta C
    Target Oncol; 2016 Apr; 11(2):143-8. PubMed ID: 26429561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
    Kammerer-Jacquet SF; Medane S; Bensalah K; Bernhard JC; Yacoub M; Dupuis F; Ravaud A; Verhoest G; Mathieu R; Peyronnet B; Brunot A; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
    Target Oncol; 2017 Aug; 12(4):487-494. PubMed ID: 28550387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.
    Nunes-Xavier CE; Angulo JC; Pulido R; López JI
    Curr Urol Rep; 2019 Jan; 20(1):1. PubMed ID: 30645700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis.
    Lee JH; Kim YJ; Ryu HW; Shin SW; Kim EJ; Shin SH; Park JY; Kim SY; Hwang CS; Na JY; Shin DH; Kim JY; Lee HJ
    Diagn Pathol; 2023 Mar; 18(1):36. PubMed ID: 36894965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
    Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
    Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.
    Alaghehbandan R; Stehlik J; Trpkov K; Magi-Galluzzi C; Condom Mundo E; Pane Foix M; Berney D; Sibony M; Suster S; Agaimy A; Montiel DP; Pivovarcikova K; Michalova K; Daum O; Ondic O; Rotterova P; Dusek M; Hora M; Michal M; Hes O
    Ann Diagn Pathol; 2017 Aug; 29():17-22. PubMed ID: 28807336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
    Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
    Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
    Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
    Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
    Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma.
    Qu F; Ye J; Pan X; Wang J; Gan S; Chu C; Chu J; Zhang X; Liu M; He H; Cui X
    J Drug Target; 2019 Jan; 27(1):67-74. PubMed ID: 30183478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
    Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
    Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays: Impact of the Architecture Pattern and the Number of Cores.
    Gagné A; Enlow W; Pigeon MA; Orain M; Turcotte S; Bossé Y; Joubert P
    Am J Surg Pathol; 2018 May; 42(5):687-694. PubMed ID: 29309297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.